Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Information from blood samples may help us for choosing the best treatment in future
personalized medicine. Natalizumab (NTZ) a current treatment for MS can be used as a second
line therapy if a suboptimal response to disease modifying drugs. When to introduce NTZ is
not consensual. The investigators hypothesized that biological information could rationalize
choice and thus designed a prospective open label trial to test biological markers before
treatment.